RESUMEN
Hyperglycemia with or without blood glucose in diabetes range is an emerging finding not uncommonly encountered in patients with COVID-19. This work is to investigate the association between serum alpha-1-antitrypsin, hyperglycemia, and clinical outcomes in COVID-19, and community-acquired pneumonia, gastric cancer and renal cell carcinoma. Alpha-1-antitrypsin levels in serum was determined by the immunoturbidimetric method. We have set the level of alpha-1-antitrypsin in patients with community-acquired pneumonia and COVID-19 with or without hyperglycemia. Levels of alpha-1-antitrypsin in COVID-19 patients with hyperglycemia who survived > those who did not survive. Concentration of alpha-1-antitrypsin levels in COVID-19 men-patients with hyperglycemia who survived was significantly higher than compared with COVID-19 women-patients with hyperglycemia who survived. The obtained data convincingly demonstrate the value of testing the level of alpha-1-antitrypsin in the blood as one of the important indicators of the effectiveness of cancer diagnosis and prognosis.
RESUMEN
Circulating cell-free DNA is a possible marker of not only apoptosis, but also COVID-19 in pregnant, which can also be a trigger factor for premature birth and predicts prenatal hypoxic-ischemic encephalopathy injury in newborns. DNA fragmentation in tissues and blood plasma was measured with the diphenylamine assay. The material for the study was the peripheral blood from pregnant women and newborns, cord blood, tissue of the placenta. A comparison of the level of cfDNA in the serum of healthy pregnant and pregnant women with premature birth suggests a high level of it in women with premature birth. Pregnant women with COVID-19 had significantly higher cfDNA values as compared to those in healthy pregnant women in cord blood, placenta and in newborns from women with COVID-19. The level of cfDNA increased with the severity of neonatal hypoxicischemic encephalopathy injury in newborns from women with premature birth.